Search
Daclizumab
go.drugbank.com/drugs/DB00111ApprovedInvestigationalWithdrawnDespite being approved for use, Zinbryta (daclizumab)'s complex pre-existing safety profile consisting of its restricted availability through a Risk Evaluation and Mitigation Strategy program [L1738] and … Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences.
Categories: Interleukin-2 Receptor Antagonist, Interleukin-2 Receptor Blocking AntibodyMM-093
go.drugbank.com/drugs/DB05512InvestigationalCurrent studies are assessing MM-093’s potential to improve the treatment of autoimmune disease. … MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults
Sarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationals Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients … The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well [L4814].
Categories: P-glycoprotein inhibitorsAbdavomeran
go.drugbank.com/drugs/DB15695Investigational[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein together with a "foldon" trimerization domain derived … BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.
Synonyms: BNT162b1 SARS-CoV-2 VaccineNKG2D-ACE2 CAR-NK Cell
go.drugbank.com/drugs/DB15727InvestigationalThe ACE2 is a receptor for SARS-Cov-2, binding to the S-protein of the viral envelope and competitively inhibiting SARS-Cov-2 infection of type II alveolar epithelial cells. … The GM-CSF acts as a neutralizer for the CAR-T cell-mediated cytokine release and neurotoxicity.
Barnidipine
go.drugbank.com/drugs/DB09227InvestigationalThe active component is composed of a single optical isomer (*3'S, 4S* configuration), which is the most potent and longest-acting of the four enantiomers [A31567]. … after a 1-year and 2-year follow-up period in 91% of the patients who had an initial response to the drug [A7842].
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingRosuvastatin
go.drugbank.com/drugs/DB01098ApprovedInvestigationalfound in clinical studies to result in a 45.8% to 54.6% decreases in LDL cholesterol levels, which is about three-fold more potent than [atorvastatin]'s effects on LDL cholesterol. … as well as the need for surgical revascularization or angioplasty following a heart attack.
Mixtures: ROSUVINA LEGRAND® E 10/40, ROSUVINA LEGRAND® E 10/20Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsEtanercept
go.drugbank.com/drugs/DB00005ApprovedInvestigationalIt is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA). … Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids.
Products: ENBREL 25MG PUL+LSM GEF SP, ENBREL 25 MG/0,5 ML SC ENJEKSIYONLUK COZELTI İÇİN KULLANIMA HAZIR ENJEKTÖR, 8 ADETLeuprolide
go.drugbank.com/drugs/DB00007ApprovedInvestigationalLeuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). … [A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron™ by Abbvie Endocrine Inc.
International brands: Prostap SR, Prostap 3Products: LUCRIN DEPOT-3 M 11,25 IM/SC ENJEKSIYONLUK FLAKON, 1 ADET, LUCRIN DEPOT-3,75 MG IM/SC ENJEKSIYONLUK FLAKON, 1 ADETUrokinase
go.drugbank.com/drugs/DB00013ApprovedInvestigationalWithdrawnUrokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. … [A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943] Urokinase was granted FDA approval on 16 January 1978.[L12138]
Products: Kinlytic Open-cath, UROKINASE KGCC INJ. 250000 IU FLAKON, 1 ADET